OBJECTIVES In Sweden, reports indicate surprisingly large regional variation in prescription of biological drugs despite a growing number of clinical studies describing their beneficial effects and guidelines by professional organizations and agencies. Our objectives were to ascertain whether there is also variation between individual rheumatologists in prescribing biologics to patients with rh...

OBJECTIVE This study examined plaque psoriasis (PsO) patient characteristics across injectable biologics. METHODS Data were collected from 400 US dermatologists randomly selecting five charts each for patients with PsO (patient n  =  2000): adalimumab (ADA; n  =  447), etanercept (ETA; 539), ustekinumab (UST) 45 mg (511) and UST 90 mg (503). Physicians had to have been in practice 2-30 years,...

Anti-tumor necrosis factor (anti-TNF) biologics are effective in the treatment of rheumatoid arthritis (RA); however, it is still not clear whether this treatment promotes the development of malignancies such as lymphoma. Human T-lymphotropic virus type 1 (HTLV-1), which is a causative agent of adult T-cell lymphoma (ATL), is prevalent in Japan. Many HTLV-1-positive patients with RA are assumed...

Methods The analysis includes data about 435 patients with JIA who have been getting Biologics in 2005 2014. The average age of patients is 10,5 years (from 1,5 to 18 years). Disease duration is 7 yrs avg (from 3 to 14 years). Clinical characteristics: soJIA 70 (17%), JIA with polyarthicular course (poly) 257 (61%), JIA oligo – 38 (9%), 51 (12%) patients suffered from active uveitis. Results Du...

Objective: To compare drug survival rates in patients with rheumatoid arthritis (RA) who start on a biologic agent to a control group of patients with a change in DMARD therapy after previous DMARD failure. Patients and Methods: Patients with RA enrolled in the German biologics register between May 2001 and September 2003 were included in the study. Data were available for 511 patients treated ...

Objectives: Several biologics therapy reportedly regress gastric amyloid deposition in AA amyloidosis patients, but it is uncertain whether they can also regress renal amyloid deposition. We carried out serial renal biopsy to clarify the regression of amyloid deposition in kidney by biologics. Methods: After the diagnosis of AA amyloidosis was determined by gastric biopsy to rheumatoid arthriti...

Psoriasis patients with moderate to severe disease often present with depression and insomnia. Treatment targeting both psoriasis and psychological comorbidities is needed to improve the quality of life of these patients.In this nationwide cohort study, a total of 980 patients with psoriatic arthritis or psoriasis who had received nonbiological disease-modifying antirheumatic drugs and biologic...

OBJECTIVES During the past decade, the position of biologics in the therapeutic armamentarium, the number of approved indications and the number of available biologics have changed. Available data on (long-term) safety might thus pertain to patient populations not comparable with contemporary patients. The aim of this study was to assess the extent to which contemporary patients who start or sw...

-The development of biologic therapy has substantially improved the treatment of psoriasis and psoriatic arthritis. At the same time, the elevated cost of biologics has prompted debate on the economic sustainability of the public health system. -As patents expire for biologics, business interests and the high capacity of today’s biotechnology industry have encouraged laboratories to develop new...